[ad_1]
NEW HOPE, Pa., March 7, 2024 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO, “Orchestra BioMed” or the “Company”) is a biomedical company operating through Venture, a Reward-sharing partnership that accelerates delivery of high-impact technology to patients, today announced that company management will be present and participate in one-on-one meetings at multiple conferences through March 2024.
Details of the presentation are below.
Oppenheimer Annual Healthcare Medical Technology and Services Conference
Format: Company Introduction
date: March 12, 2024
time: 3:20 PM (ET)
Webcast: https://wsw.com/webcast/oppenheimer34/obio/2767483
Barclays 26th Annual Global Healthcare Conference
Format: fireside chat
date: March 14, 2024
time: 11:15 a.m. Eastern Time
A live audio webcast of Oppenheimer’s presentation can be accessed through the Investors section of the Company’s website: https://investors.orchestrabiomed.com/news-events/events. An archived replay of the webcast will be available on the Company’s website for 90 days following the live event.
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company that accelerates the delivery of high-impact technologies to patients through shared risk-reward partnerships with leading medical device companies. Orchestra BioMed’s partnership business model focuses on establishing strategic collaborations with leading medical device companies to drive successful global commercialization of the products they develop. Orchestra BioMed’s lead product candidate is atrioventricular septal modulation (AVIM) therapy, also known as BackBeat Cardiac Neuromodulation Therapy (CNT™), for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to treat atherosclerotic arterial disease, a leading cause of death worldwide. Orchestra BioMed has established a strategic partnership with Medtronic, one of the world’s largest medical device companies, to jointly develop and commercialize AVIM therapy for the treatment of hypertension in patients with pacemaker indications. Terumo has established a strategic partnership. technology, development and commercialization of Virtue SAB for the treatment of arterial disease. Orchestra BioMed has additional product candidates and plans to expand its product pipeline through acquisitions, strategic partnerships, licensing and organic development.For more information about Orchestra BioMed, please visit www.orchestrabiomed.comand follow us LinkedIn.
forward-looking statements
Certain statements contained in this press release that are not historical facts are forward-looking statements intended to comply with the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” and “plan.” , “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends, or are not statements of historical events. These forward-looking statements include, but are not limited to, statements regarding the potential efficacy and safety of the Company’s commercial product candidates, the ability of the Company’s partners to accelerate clinical development, and the Company’s late-stage development plans, strategic partnerships and plans to expand its product pipeline. These statements are based on various assumptions (whether or not identified in this release) and the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are for illustrative purposes only and are not intended to be, and shall not be relied upon as, guarantees, guarantees, predictions or express statements of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from those hypothesized. Many actual events and circumstances are beyond the Company’s control. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; related to regulatory approval of the Company’s product candidates and the ongoing regulatory approval of the Company’s product candidates, if approved risks; the timeline for expected regulatory and business milestones and the Company’s ability to achieve them; the impact of competing products and product candidates; and the risk factors discussed under the heading “Item 1A.” “Risk Factors” in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2023, as updated with any risk factors disclosed under the heading “Item 1A.” “Risk Factors” in the Company’s subsequent quarterly reports on Form 10-Q.
The Company operates in a highly competitive and rapidly changing environment. New risks emerge from time to time. In light of these risks and uncertainties, the Company cautions not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company does not plan and undertakes no obligation to update any forward-looking statements made herein, except as required by law.
References to websites and social media platforms
Reference to information contained on or accessible through websites and social media platforms does not constitute an incorporation of information contained on or accessible through such websites or social media platforms, and you Such information should not be considered part of this press release.
Investor contact information:
Bob Yedid
life sciences consultant
(646)597-6989
Bob@lifesciadvisors.com
Media contact information:
Kelsey Kirk-Ellis
biomedical orchestra
(484)682-4892
kkirkellis@orchestrabiomed.com
[ad_2]
Source link